Organon (OGN) stock dropped 13% after the company's Q1 results indicated its plans to cut dividends to $0.02/share amid a ...

Organon stock cut their dividend by over 90%. There are lessons here for all income investors. Click here to find out what ...

Pharmaceutical company Organon (NYSE:OGN) reported in Q1 CY2025, but sales fell by 6.7% year on year to $1.51 billion. Its ...

Shares of Organon & Co. fell to a record low on Thursday after a series of analyst downgrades and price target cuts followed ...

BofA analyst Jason Gerberry lowered the firm’s price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating ...

The Jersey City, N.J., pharmaceutical company cut its quarterly dividend to 2 cents a share, down from the prior 28 cents a share. Chief Executive Kevin Ali said the company reset its ...

Despite a 4% revenue decline, Organon & Co (OGN) sees promising growth in key segments like Nexplanon and Vtama, while focusing on debt reduction and strategic expansion.

The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.

The Jersey City, New Jersey-based company said it had net income of 33 cents per share. Earnings, adjusted for one-time gains and costs, were $1.02 per share. The results topped Wall Street ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago. These figures ...

Organon reaffirmed its full-year 2025 revenue guidance of $6.125-6.325 billion, with the midpoint slightly below the consensus estimate of $6.292 billion. The company also expects to generate over ...